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Abstract
Objectives—Cirrhosis occurs in 5-10% of CF (cystic fibrosis) patients, often accompanied by 
portal hypertension. We analyzed three adverse liver outcomes, variceal bleeding (VB), liver 
transplant (LT), and liver death (LD), and risk factors for these in CF Foundation Patient Registry 
(CFFPR) subjects with reported cirrhosis.
Methods—We determined 10-year incidence rates for VB, LT, LD, and all-cause mortality 
(ACM), and examined risk factors using competing risk models and Cox-proportional hazard 
regression.
Results—From 2003-2012, 943 participants (41% female, mean age 18.1 years) had newly 
reported cirrhosis; 24.7% required insulin, 85% had prior pseudomonas. Seventy-three subjects 
had reported VB; 38 with first VB and new cirrhosis reported simultaneously and 35 with VB after 
cirrhosis report. 10-year cumulative VB, LT, and LD rates were 6.6% (95% Confidence Interval 
(CI): 4.0, 9.1%), 9.9% (95% CI: 6.6%, 13.2%), and 6.9% (95% CI: 4.0%, 9.8%), respectively, 
with an ACM of 39.2% (95% CI: 30.8, 36.6%). ACM was not increased in subjects with VB 
compared to those without (HR 1.10, 95% CI: 0.59, 2.08). CF related diabetes (CFRD (hazard 
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ratio (HR): 3.141, 95% CI:1.56, 6.34) and VB (HR: 4.837, 95% CI: 2.33, 10.0) were associated 
with higher LT risk while only worse lung function was associated with increased LD in 
multivariate analysis. Death rate among subjects with VB was 24% with LT and 20.4% with native 
liver.
Conclusions—VB is an uncommon complication of CF cirrhosis and can herald the diagnosis, 
but does not affect ACM. Adverse liver outcomes and ACM are frequent by 10 years after 
cirrhosis report.
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Introduction
Cystic fibrosis-related liver disease (CFLD) has been hypothesized to result from absent or 
abnormal bicarbonate flow through the cystic fibrosis transmembrane regulator (CFTR), 
leading to increased viscosity of bile and ultimately bile stasis and obstruction.[1, 2] Even in 
the absence of cholestasis, the consequences of viscous bile can be intermittent intrahepatic 
ductal obstruction, inflammation, and subsequent fibrosis. While hepatic manifestations of 
cystic fibrosis (CF) are common and may include elevated serum transaminases, hepatic 
steatosis and imaging abnormalities, only 5-10% of CF patients progress to advanced liver 
disease with cirrhosis and portal hypertension.[3-5] When cirrhosis occurs, it presents early, 
almost uniformly before the second decade of life.[6-9] It has been estimated that more than 
half of patients with CF cirrhosis have esophageal varices.[3] Gastrointestinal bleeding from 
esophageal varices has been reported to occur often in CF patients with portal hypertension 
and frequently occurs in the context of preserved hepatic synthetic function.[4, 6, 10] 
Previous studies of the frequency and prevalence of variceal hemorrhage in CF cirrhosis 
with portal hypertension have primarily come from quaternary referral centers and have 
reported variceal bleeding (VB) rates of 40-50%.[6, 11] To our knowledge, there is no large 
population series to estimate the frequency of variceal hemorrhage in CF cirrhosis.
The CF Foundation Patient Registry (CFFPR) database prospectively collects demographic 
and encounter-based clinical data for approximately 85–90% of the United States (US) CF 
population.[12] It provides a rich tool for the analysis of CF complications, and since 2003, 
has captured enhanced liver-related data that can be systematically queried to investigate 
specific outcomes such as variceal hemorrhage in individuals with cirrhosis. As such, the 
goal of this study was to investigate the frequency and risk factors for variceal hemorrhage 
and adverse liver outcomes in children and adults with CF cirrhosis.
Methods
Study population
Participant data for this study were collected from the CFFPR (Bethesda, Maryland). The 
data is entered electronically for all clinical encounters by designated staff at each CF 
Foundation-accredited Care Center. The data entry form contains a field for the clinician to 
select for cirrhosis and another to select for VB; when appropriate, cause of death may also 
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be specified with liver-related death as an option. As the CF registry does not distinguish 
cirrhosis from non-cirrhotic portal HTN, the term “cirrhosis” is used for the purpose of this 
study since both clinical entities can lead to the same adverse liver outcomes. Utilizing the 
CFFPR, we performed a cohort study to evaluate the incidence rate of and risk factors 
associated with variceal bleeding and adverse liver outcomes in CF subjects with reported 
cirrhosis. As variceal bleeding events were only captured after January 1, 2003 in the 
CFFPR, we limited our study population to individuals newly reported to have cirrhosis of 
their native liver from January 2003 to December 2012 (see Figure 1, consort diagram). IRB 
exemption of this study was obtained through the University of Michigan Institutional 
Review Board.
Outcomes and risk factors
We analyzed three time-to-event adverse liver outcomes: time from cirrhosis report to VB, 
liver transplant (LT), and liver-related death (LD). Secondarily, we also investigated time to 
all-cause mortality (ACM). Potential risk factors included demographics (race, age at time of 
cirrhosis diagnosis, gender), markers of CF disease severity (CF genotype, FEV1% 
predicted, FVC% predicted), Pseudomonas aeruginosa (PA) culture status, body mass index 
(BMI, kg/m2), and CF-related diabetes (CFRD). Severe genotype was defined as having 
both CFTR mutations in classes I-III; mild genotype was defined as one or more mutations 
in class IV-V.
Statistical analysis
Descriptive statistics were calculated for the total study population and compared between 
cirrhotic subjects who had VB reported on the same encounter when cirrhosis was first 
reported, those whose first VB was reported after the report of cirrhosis, and those with no 
reported VB during the study follow-up period. Continuous variables were compared using 
ANOVA test and Student's t test allowing for unequal variances and categorical variables 
with a Chi-square or Fisher's exact test when appropriate.
To estimate cumulative incidence of VB, liver transplant, and liver-related death, a 
competing risk model was used. For the analysis of VB, liver transplant and death were 
treated as competing events. For the analysis of liver-related death, other death and liver 
transplant were treated as competing events. For the analysis of liver transplant, ACM was 
treated as a competing event. Kaplan-Meier curves were used to estimate the incidence rate 
of total mortality in the study cohort over time. Cause-specific hazard competing risk models 
with time-varying covariates were used to study risk factors for all three adverse liver 
outcomes. Cox-proportional hazard regression models with time-varying covariates were 
used to study risk factors for all-cause mortality. To study cumulative incidence rate of VB 
from time of cirrhosis report, we focused on cirrhotic subjects who had no VB history at the 
time of diagnosis of cirrhosis, i.e., subjects who had VB at the time cirrhosis was reported 
were excluded. For analysis of liver transplant, liver death, or all-cause mortality, all 
identified patients with cirrhosis and follow-up were included. FEV1% predicted, ever 
positive for Pseudomonas aeruginosa (PA) in a respiratory tract culture, most recent PA 
status, BMI, and CFRD were included as time-varying covariates in the regression analyses 
for all outcomes. In the regression analysis for all-cause mortality, liver transplant and liver-
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related death, one additional time-varying covariate, history of variceal hemorrhage, was 
also added. Since the exact date of liver transplantation is not captured in CFFPR (only the 
year of liver the transplantation is entered), we imputed the liver transplant date as July 1 in 
the reported year. Because frequent encounter data were available for this CF cohort of 
patients, last-value-carried-forward method was implemented for imputing time-varying 
covariates at the time of events. Both univariate and multivariate analysis results were 
presented.
Results
Study population
Among 35,516 active CFFPR subjects from January 2003 to December 2012, 1290 (3.6%) 
were reported to have cirrhosis (Figure 1, consort diagram). Among these, 970 registry 
subjects with their native liver were newly reported to have cirrhosis during this period and 
were evaluated for subsequent VB. Excluding 27 subjects who had no further follow-up the 
remaining 943 cirrhosis subjects were included in the analysis (Figure 1). 41% of the study 
subjects were female, and 3.4% of these subjects had mild CFTR mutations (compared to 
8.2% in the overall CF population). At the time of report of cirrhosis, the mean age of the 
study population was 18.1 (median=15.7, SD=11.6) years; 24.7% subjects were on chronic 
insulin and 84.6% subjects had history of PA-positive culture. Among the study cohort 169 
(17.5%) patients died and 49 (5.2%) received a liver transplant. Repeated measures of 
severity of CF were available with a median of 60 BMI measurements, 40 FEV1% 
measurements, and 78 PA cultures per subject during the follow-up period. Excluding 38 
subjects who had their first variceal hemorrhage recorded on the same day that cirrhosis was 
first recorded, 905 were included in the analyses for incident VB. Figure 1 shows the consort 
diagram and Suppl Table 1 shows the baseline characteristics of the study population. No 
baseline characteristics were found to be significantly different among the three groups: 
those without VB, those with VB and cirrhosis reported concurrently, and those with 
cirrhosis reported who subsequently had VB.
Variceal bleeding, liver transplant, and liver-related death over time
Variceal bleeding—Supplemental Figure 1 demonstrates age at first report of VB. The 
mean age at first VB was 18.8 years (median: 16.0, range 0.89 – 45.14). For two subjects, 
VB was recorded following liver transplant. Among the 71 subjects who had experienced 
VB with their native liver, there was a peak in adolescence, with VB being uncommon after 
30 years of age. Among the 905 subjects included for the analysis of VB incidence, 35 had 
VB reported during a mean follow-up period of 3.6 years (range 0.003-10 years). The 
estimated 10-year cumulative VB rate was 6.6% (95% confidence interval (CI): 4.0, 9.1%) 
(Figure 2A).
Liver transplant (LT)—Of the 870 subjects with no reported VB, 34 (3.8%) underwent 
LT. In contrast, among the 73 subjects in whom a VB was reported, 15 (20.6 %) underwent 
LT. Of the 15 patients with VB who were transplanted, 8 received LT within one year of 
reporting a VB. The estimated 10-year cumulative LT rate was 9.9% (95% CI: 6.6%, 13.2%) 
(Figure 2B)
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Liver-related death—The estimated 10-year cumulative liver-related death rate was 6.9% 
(95% CI: 4.0%, 9.8%) (Figure 2C)
Adverse liver outcomes—Overall, in 10 years, among the above 905 subjects who were 
followed and had not had a VB reported at the time when cirrhosis was reported, adverse 
liver outcomes (variceal hemorrhage, liver transplant, or death due to liver failure) were 
observed in 96 subjects. The estimated 10-year cumulative rate of any adverse liver-related 
outcomes was 20.4% (95% CI: 15.4, 25.5%).
All-cause mortality—Among the 943 cirrhosis subjects who were followed, the estimated 
10-year cumulative total death rate among all patients with cirrhosis was 39.2% (95% CI: 
30.8, 46.6%) (Figure 2D).
Risk factors for adverse liver outcomes (summarized in Table 1)
Variceal bleeding (VB)—In univariate analysis, among reported cirrhosis subjects with 
no prior VB at the time of initial cirrhosis report, only worse FEV1% predicted showed a 
tendency (p=0.070) for higher risk of VB (Supplemental Table 2A). In multivariate analysis, 
after adjusting all other risk factors, older age at cirrhosis report was the only risk factor 
associated with lower risk of VB; a one year increase in age was related to a 5% (95% CI: 
0.3%, 10.5%) reduction in risk. FEV1%, severity of genotype, nutrition/BMI, and CFRD did 
not significantly affect the risk of VB.
Liver transplant (LT)—In the univariate model for LT, CFRD was associated with a 2.6-
fold increase in risk (HR 2.590 for chronic insulin use vs no insulin use, 95% CI: 1.376, 
4.875) and VB was associated with a 5-fold increase in risk (HR 5.121: 95%CI: 
2.511-10.443). For both risk factors, hazard ratios were similar on multivariate analysis. In 
addition, older age was associated with decreased risk of liver transplant (HR 0.943; CI 
0.899-0.989) (Supplemental Table 2B).
Liver-related death (LD)—Gender, age, FEV1% predicted decrease, pseudomonas 
positivity, decreased BMI, CFRD, and VB were all associated with increased liver related 
mortality on univariate analysis. VB was associated with a 4-fold increase in risk (HR 4.11: 
95%CI: 1.83 - 9.22). On multivariate analysis, only FEV1% predicted decrease was 
associated with increased liver-related mortality (Supplemental Table 2C).
Causes of death and risk factors for death
Almost two-thirds of deaths among these cirrhotic subjects were pulmonary related (Table 2 
displays causes of death by VB history and LT status in subjects with cirrhosis). Among CF 
subjects who had VB reported, death was reported for 20.0% in those with and 24.1% in 
those without LT (given unknown actual date of LT and low count of LT, no survival analysis 
was carried out to compare effect of LT on risk of mortality). Among those who did not have 
VB reported, death was reported in 5.9% in the group who received LT and in 17.9% in the 
group without LT. Among reported cirrhosis subjects with their native liver who had not had 
VB, 20.0% (30/150) of deaths were due to liver disease/liver failure compared to 35.7% 
Ye et al. Page 5
J Pediatr Gastroenterol Nutr. Author manuscript; available in PMC 2019 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
(5/14) in the VB native liver group. Five of the 49 subjects who received LT died within a 
median of 2.5 years (range 0.28-8.4 years), but none were due to liver disease/liver failure.
Supplemental Table 2D shows the Cox proportional hazard regression model results for all-
cause mortality (ACM). In univariate analysis, a 10% reduction of FEV1% was associated 
with a 78.6.0% increase in risk of ACM (HR for 10% increase in FEV1%: 0.56, 95% CI: 
0.51, 0.61); low BMI and CFRD were strongly associated with increased mortality risk. On 
multivariate analysis, older age at first reported cirrhosis (HR: 1.032, 95% CI: 1.016, 1.049), 
and chronic insulin requirement (HR for chronic insulin use vs. normal glucose intolerance: 
2.45, 95% CI: 1.57, 3.83) were all associated with higher risk of ACM in addition to lower 
FEV1%. Recent positive status of PA (but not lifetime history of positivity) was associated 
with lower risk (HR: 0.65, 95% CI: 0.45, 0.95) of all-cause mortality. Notably, history of VB 
did not increase risk of all-cause mortality in this cohort.
Discussion
This longitudinally captured registry based study demonstrates that variceal hemorrhage is 
not very common in CF cirrhosis, with less than 10% of patients experiencing variceal 
hemorrhage in the 10 years after the report of cirrhosis. This bleeding rate is substantially 
less than the 40 or 50% rate that has previously been reported in the literature among 
patients with CF cirrhosis.[3, 6, 11] Bleeding typically occurs in adolescence, with rare 
occurrence under 9 years or over 40 years of age, reaffirming the early onset of CF cirrhosis.
[9] In our study, cirrhosis had not previously been reported in half of the patients with 
variceal bleeding until the sentinel bleeding event. The database does not contain reliable 
data on platelet count and provides no data on spleen size, so it is impossible to determine 
whether laboratory or physical findings might have suggested a diagnosis of cirrhosis or 
portal hypertension earlier. Earlier detection of advanced CF liver disease would have 
implications for immunizations (hepatitis A, B, pneumococcus), anticipatory guidance 
(avoiding NSAIDs, recognizing signs and symptoms of GI bleeding), and in prophylactic 
management in adults such as screening endoscopy, propranolol or variceal band ligation).
[13-16]
Identification of risk factors for bleeding in CF patients with cirrhosis and portal 
hypertension would also be helpful in managing and counseling patients. In multivariate 
analysis, only younger age at report of cirrhosis was identified as a risk factor for variceal 
bleeding. Commonly identified complications of CF such as decreased pulmonary function, 
compromised nutritional status and CFRD were not found to be risk factors. It is unclear 
why younger age at reporting of cirrhosis is a risk factor for variceal bleeding. Earlier 
recognition of cirrhosis may be associated more aggressive and rapidly progressive form of 
CF liver disease. Considering overall mortality rate increases as patients become older, it is 
also possible that death due to lung failure played a role.
By univariate and multivariate analysis, CFRD and variceal bleeding were associated with 
an increased risk of liver transplantation. In contrast, while low BMI, CFRD, variceal 
bleeding and other factors were significant on univariate analysis, on multivariate analysis, 
only poor lung function (decreased FEV1%) was associated with increased risk of liver-
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related mortality. Chronic antibiotic exposure in patients with pulmonary exacerbations due 
to CF-specific pathogens and an acidic, more permeable gastrointestinal tract may not only 
alter the intestinal microbiome but trigger an inflammatory cascade that leads to Kupffer cell 
mediated liver injury.[17] Chronic cough may also lead to increased intra-abdominal 
pressures affecting splanchnic flow. Compromised nutritional status with advanced lung 
disease might also impact tissue elasticity or healing, promoting variceal bleeding. Insulin 
resistance has been known to be associated with worse outcomes in other liver conditions 
such as fatty liver disease; similarly, CF-related diabetes (CFRD) may be a modifier of liver 
disease by interfering with healing and immune response to infections. CFRD and insulin 
resistance could conceivably be associated with another genetic modifier of the liver disease.
[18, 19]
Our data demonstrate substantial overall mortality among reported CF cirrhosis patients, 
with 39.2% dying within 10 years of initial report and at a mean age of 18 years. By 
comparison, mortality per decade between ages 20 and 50 years was only 20%-30% in two 
modern era analyses of unselected CF subjects.[21, 22] Importantly and surprisingly, 
however, variceal hemorrhage was not associated with increased all-cause mortality, 
although it was associated with more liver-related mortality on univariate analysis only. 
Furthermore, two-thirds of deaths were attributed to lung disease in this cirrhotic population, 
highlighting the critical role of declining lung function in patients with CF cirrhosis.
Cirrhotic subjects who had experienced variceal hemorrhage were 5 times more likely to be 
transplanted and were transplanted quickly (more than half within a year of variceal 
bleeding). Gastrointestinal bleeding has often prompted consideration of liver transplant in 
CF, and our data confirms this.[23-26]. Further study is needed regarding indications and 
timing of liver transplantation in CF liver disease and the impact of variceal bleeding on 
decision-making.
This study represents an analysis of nearly 1000 North American children and adults with 
reported CF cirrhosis and provides important data regarding the incidence of variceal 
hemorrhage, adverse liver outcomes, and related risk factors. As with any registry-based 
studies, we encountered limitations secondary to incomplete, inadequate, or misclassified 
data. The registry forms did not differentiate between cirrhosis and non-cirrhotic portal 
hypertension, although the outcomes we studied pertain to both. This registry-based study is 
less vulnerable to ascertainment bias than single-center reports, which could partly explain 
the lower rate of variceal bleeding observed in this population. Due to limitations of the 
registry, we could not account for the impact of potential primary prophylaxis in some 
(likely adult) patients, which may have decreased the bleeding rate. Lastly, the number of 
subjects with reported variceal bleeding targeted in this analysis is small as patients with 
variceal bleeding who were reported to have cirrhosis on the same date of the bleeding event 
could not be included in the survival analysis for first variceal bleeding, hence may have led 
to further underestimation of the rate. (In Supplemental Figure 2 we provide cumulative 
incidence curves from birth rather than from cirrhosis diagnosis with an explanatory 
footnote.) In recent years, improvements have been made to the liver-related case report 
forms in the CF registry, which should serve to improve the quality of future liver-specific 
Ye et al. Page 7
J Pediatr Gastroenterol Nutr. Author manuscript; available in PMC 2019 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
data. This study underscores the importance of collecting prospective clinical data regarding 
liver disease in this vulnerable population.
This study yields several key messages. Variceal bleeding in CF liver disease is a much less 
common than previously thought, and often heralds the recognition of unsuspected cirrhosis. 
Except for younger age at cirrhosis diagnosis, there were no additional risk factors 
associated with increased risk of variceal bleeding. Notably, variceal hemorrhage does not 
impact all-cause mortality in CF patients but does coincide with other adverse liver 
outcomes, including liver transplantation. This differs significantly from the adult experience 
with cirrhosis where substantial mortality (up to 15%) is associated with variceal bleeding.
[27] Ultimately, 10-year all-cause mortality is substantial in patients with CF cirrhosis at 
nearly 40%, though death is most commonly due to pulmonary complications. The role and 
timing of liver transplantation in CF cirrhosis complicated by variceal hemorrhage warrants 
data with higher fidelity before formal recommendations can be made. Prospective detailed 
studies of children and adults with early identification of CF cirrhosis are needed.
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CF Cystic Fibrosis
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VB variceal bleeding
ALO adverse liver outcomes
LT liver transplant
LD liver death
ACM all-cause mortality
PA pseudomonas aeruginosa
HR hazard ratio
CI confidence interval
FVC forced vital capacity
CFRD CF-related diabetes
CFLD cystic fibrosis-related liver disease
CFTR cystic fibrosis transmembrane regulator
CFFPR CF Foundation Patient Registry
FEV forced expiratory volume
BMI body mass index
NSAID non-steroidal anti-inflammatory drug
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What is known
• Cirrhosis occurs in 5-10% of patients with Cystic Fibrosis (CF).
• Variceal bleeding is common in CF cirrhosis but synthetic function is usually 
preserved until late in the course
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What is new
• The cumulative rate of variceal bleeding in this large population of CF 
patients after first report of cirrhosis was only 6.6% at 10 years, while liver 
transplant was 9.9%, liver death 6.9%, overall adverse liver outcomes 20%, 
and all-cause mortality 39%.
• CF-related diabetes and VB are significant risk factors for liver transplant in 
CF cirrhosis
• All-cause mortality was not impacted by variceal bleeding.
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Figure 1. 
Consort Diagram of Study Population
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Figure 2. 
Cumulative Incidence Curves for Variceal Bleeding (Among Patients Who Had No History 
of VB at the Time of Report of Cirrhosis) (A), Liver Transplant (B), Liver Related Death 
(C), and All-Cause Mortality (D)
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Table 1
Summary of Findings from Cause-Specific Competing Risk Regression Model
Outcome Significant on Univariate Analysis (HR) Significant on Multi-Variate Analysis (HR)
VB Age at 1st Reported Cirrhosis (0.895)
LTP Age at 1st Reported Cirrhosis (0.899)
CFRD (2.590) CFRD (3.141)
VB (5.121) VB (4.837)
LRM Gender (2.271)
Age (1.044)
FEV1↑ (0.591) FEV1↑ (0.674)
PA ever (2.998)
BMI under (6.647)
CFRD (5.196)
VB (4.110)
ACM Age (1.055) Age (1.032)
FEV1↑ (HR 0.560) FEV1↑ (0.623)
Recent PA (0.649)
BMI under (5.590)
CFRD (5.563) CFRD (2.454)
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Table 2
2A. Death (count, %) by Variceal Bleeding (VB)and Liver Transplant (LT) Status
No VB (N=870) VB (N=73)
No LT N=836 LT N=34 No LT N=58 LT N=15
Total number of deaths (%) 150 (17.9%) 2 (5.9%) 14 (24.1%) 3 (20.0%)
2B. Cause of Death by Variceal Bleeding and Liver Transplant Status
Primary cause of death (Count (%)) No VB or LT N=150 No VB, had LT N=2 Had VB, no LT N=14 Had VB hadLT N=3
Respiratory/cardiorespiratory 101 (67.3%) 0 8 (57.1%) 2 (66.7%)
 Liver Disease/Liver Failure 30 (20.0%) 0 5 (35.7%) 0
 Trauma 0 0 0 0
 Suicide 0 1 (50%) 0 0
 Transplant related: Other^ 4 (2.7%) 1 (50%) 1 (7.1%) 1 (33.3%)
 Other 9 (6.0%) 0 0 0
 Unknown 6 (4.0%) 0 0 0
*Among the 15 who had variceal bleeding and transplant, two had transplant before the first reported variceal hemorrhage, one of whom died of 
respiratory/cardiorespiratory cause, the other was alive at the end of follow-up.
^
Lung transplant is included here
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